Arcus Biosciences (RCUS) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Arcus Biosciences (NYSE: RCUS) in the last few weeks:

• 5/11/2026 – Arcus Biosciences had its price target raised by Morgan Stanley from $20.00 to $22.00. They now have an “equal weight” rating on the stock.
• 5/9/2026 – Arcus Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/7/2026 – Arcus Biosciences had its price target raised by The Goldman Sachs Group, Inc. from $30.00 to $34.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Arcus Biosciences was upgraded by Truist Financial Corporation to “strong-buy”.
• 4/20/2026 – Arcus Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/20/2026 – Arcus Biosciences was given a new $47.00 price target by Leerink Partners.
• 4/2/2026 – Arcus Biosciences had its price target raised by Wedbush from $37.00 to $41.00. They now have an “outperform” rating on the stock.
• 3/25/2026 – Arcus Biosciences was upgraded by Truist Financial Corporation to “strong-buy”.

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.